Detailed definition
Hypoactive sexual desire disorder (HSDD) is characterized by persistent or recurrent absence or deficiency of sexual fantasies and desire for sexual activity, causing marked distress or interpersonal difficulty. Population-based studies estimate the prevalence of distressing low desire at roughly 10% of women, rising to higher rates in midlife and post-menopause. Etiology is multifactorial: hormonal (declining ovarian estrogen and testosterone), neurobiological, psychosocial, relational, and medication-related (notably SSRIs). Evidence-based treatments include: low-dose transdermal testosterone for postmenopausal women — the only intervention with high-quality evidence specifically for HSDD in this population, dosed to keep total testosterone within the female physiologic range; flibanserin (Addyi), a daily 5-HT1A agonist/5-HT2A antagonist FDA-approved for premenopausal HSDD; and bremelanotide (Vyleesi), an as-needed melanocortin-4 receptor agonist FDA-approved for premenopausal HSDD. Addressing concurrent GSM-related dyspareunia is essential, since pain itself suppresses desire.
Why it matters in menopause
For postmenopausal women with HSDD, low-dose testosterone is the most evidence-supported pharmacologic option, but no FDA-approved testosterone product for women exists in the US — so it must be prescribed off-label using a fraction of a male product or a compounded formulation. Pellet testosterone is a different and not-recommended approach because it produces supraphysiologic levels.
Related terms
Sources
External references: Wikipedia.